<li>5-htp<p>escitalopram and 5-htp both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>aceclofenac<p>escitalopram, aceclofenac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>acemetacin<p>escitalopram, acemetacin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>almotriptan<p>almotriptan and escitalopram both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>amobarbital<p>amobarbital will decrease the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>amphetamine<p>amphetamine increases toxicity of escitalopram by serotonin levels. Use Caution/Monitor. Closely monitor for signs and symptoms of serotonin syndrome (eg, agitation, tremor, tachycardia).</p></li><li>armodafinil<p>armodafinil will increase the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>aspirin<p>escitalopram, aspirin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>aspirin rectal<p>escitalopram, aspirin rectal.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>escitalopram, aspirin/citric acid/sodium bicarbonate.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>atazanavir<p>atazanavir increases levels of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased risk of serotonin syndrome.</p></li><li>atomoxetine<p>escitalopram increases levels of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>bedaquiline<p>escitalopram and bedaquiline both increase  QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely</p></li><li>boceprevir<p>boceprevir decreases levels of escitalopram by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>bortezomib<p>bortezomib will increase the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>buprenorphine subdermal implant<p>escitalopram, buprenorphine subdermal implant.
Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.</p></li><li>butabarbital<p>butabarbital will decrease the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>butalbital<p>butalbital will decrease the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>celecoxib<p>escitalopram, celecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>choline magnesium trisalicylate<p>escitalopram, choline magnesium trisalicylate.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>clopidogrel<p>escitalopram increases effects of clopidogrel by pharmacodynamic synergism. Use Caution/Monitor. SSRIs affect platelet activation; coadministration of SSRIs with clopidogrel may increase the risk of bleeding.</p></li><li>clozapine<p>escitalopram increases levels of clozapine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Plasma levels of clozapine may be increased, resulting in increased pharmacologic and toxic effects. Adjust clozapine dose as needed when initiating or discontinuing certain SSRIs. .</p></li><li>cocaine<p>escitalopram and cocaine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>crizotinib<p>crizotinib increases levels of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.<span><br><br></span>crizotinib and escitalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>crofelemer<p>crofelemer increases levels of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.</p></li><li>cyproheptadine<p>escitalopram increases and cyproheptadine decreases serotonin levels. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.</p></li><li>dabrafenib<p>dabrafenib will decrease the level or effect of escitalopram by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.</p></li><li>darunavir<p>darunavir increases levels of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Increased risk of serotonin syndrome.</p></li><li>defibrotide<p>defibrotide increases effects of escitalopram by Other (see comment). Use Caution/Monitor. 
Comment: Defibrotide may enhance effects of platelet inhibitors.</p></li><li>dexfenfluramine<p>escitalopram and dexfenfluramine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>dextroamphetamine<p>escitalopram and dextroamphetamine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>dichlorphenamide<p>dichlorphenamide and escitalopram both decrease  serum potassium. Use Caution/Monitor.</p></li><li>diclofenac<p>escitalopram, diclofenac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>diflunisal<p>escitalopram, diflunisal.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>dihydroergotamine<p>escitalopram and dihydroergotamine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>dihydroergotamine intranasal<p>escitalopram and dihydroergotamine intranasal both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>efavirenz<p>efavirenz will increase the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>eletriptan<p>eletriptan and escitalopram both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.</p></li><li>ergotamine<p>escitalopram and ergotamine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>eslicarbazepine acetate<p>eslicarbazepine acetate increases levels of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>esomeprazole<p>esomeprazole will increase the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>etodolac<p>escitalopram, etodolac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>etoricoxib<p>escitalopram, etoricoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>etravirine<p>etravirine will increase the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>ezogabine<p>ezogabine, escitalopram.
Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.</p></li><li>felbamate<p>felbamate will increase the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>fenbufen<p>escitalopram, fenbufen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>fenfluramine<p>escitalopram and fenfluramine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>fenoprofen<p>escitalopram, fenoprofen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>fluconazole<p>fluconazole will increase the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>fluoxetine<p>escitalopram and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>flurbiprofen<p>escitalopram, flurbiprofen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>fosamprenavir<p>fosamprenavir increases levels of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Increased risk of serotonin syndrome.</p></li><li>frovatriptan<p>frovatriptan and escitalopram both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>green tea<p>green tea, escitalopram. Other (see comment). Use Caution/Monitor. 
Comment: Combination may increase risk of bleeding.</p></li><li>haloperidol<p>haloperidol and escitalopram both increase  QTc interval. Use Caution/Monitor.</p></li><li>hydroxyurea<p>escitalopram, hydroxyurea. Other (see comment). Use Caution/Monitor. 
Comment: Combination may increase risk of myelosuppression.</p></li><li>ibuprofen<p>escitalopram, ibuprofen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>iloperidone<p>iloperidone increases levels of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.</p></li><li>indacaterol, inhaled<p>indacaterol, inhaled, escitalopram. QTc interval. Use Caution/Monitor. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.</p></li><li>indinavir<p>indinavir increases levels of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Increased risk of serotonin syndrome.</p></li><li>indomethacin<p>escitalopram, indomethacin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>ioflupane i 123<p>escitalopram decreases effects of ioflupane i 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration.</p></li><li>isoniazid<p>isoniazid will increase the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.<span><br><br></span>escitalopram and isoniazid both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>ketoprofen<p>escitalopram, ketoprofen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>ketorolac<p>escitalopram, ketorolac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>ketorolac intranasal<p>escitalopram, ketorolac intranasal.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>l-tryptophan<p>escitalopram and l-tryptophan both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>lamotrigine<p>lamotrigine increases toxicity of escitalopram by unspecified interaction mechanism. Modify Therapy/Monitor Closely. CNS depressants may increase the toxic effects of selective serotonin reuptake inhibitors; psychomotor impairment may be enhanced.</p></li><li>lenvatinib<p>escitalopram and lenvatinib both increase  QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.</p></li><li>lisdexamfetamine<p>escitalopram and lisdexamfetamine both increase  serotonin levels. Use Caution/Monitor.</p></li><li>lithium<p>escitalopram and lithium both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>lopinavir<p>lopinavir increases levels of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Increased risk of serotinin syndrome.</p></li><li>lornoxicam<p>escitalopram, lornoxicam.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>lsd<p>escitalopram and lsd both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>lumacaftor/ivacaftor<p>lumacaftor/ivacaftor, escitalopram. affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. In vitro studies suggest that lumacaftor may induce and ivacaftor may inhibit CYP2C19 substrates. .<span><br><br></span>lumacaftor/ivacaftor will decrease the level or effect of escitalopram by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. A higher dose of escitalopram may be required to obtain desired therapeutic effect. Escitalopram is a CYP3A and CYP2C19 substrate. Lumacaftor/ivacaftor is a strong inducer of CYP3A and has the potential to induce CYP2C19.</p></li><li>lurasidone<p>lurasidone, escitalopram.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.</p></li><li>meclofenamate<p>escitalopram, meclofenamate.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>mefenamic acid<p>escitalopram, mefenamic acid.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>meloxicam<p>escitalopram, meloxicam.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>mephobarbital<p>mephobarbital will decrease the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>mifepristone<p>mifepristone, escitalopram. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available.</p></li><li>mirtazapine<p>escitalopram and mirtazapine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>mitotane<p>mitotane decreases levels of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.</p></li><li>modafinil<p>modafinil will increase the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely.</p></li><li>morphine<p>escitalopram and morphine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>moxifloxacin<p>escitalopram and moxifloxacin both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>moxifloxacin and escitalopram both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>nabumetone<p>escitalopram, nabumetone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>naproxen<p>escitalopram, naproxen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>naratriptan<p>naratriptan and escitalopram both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>nelfinavir<p>nelfinavir increases levels of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Increased risk of serotonin syndrome.</p></li><li>olodaterol inhaled<p>escitalopram and olodaterol inhaled both increase  QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias</p></li><li>omeprazole<p>omeprazole will increase the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>osimertinib<p>osimertinib and escitalopram both increase  QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.</p></li><li>oxaprozin<p>escitalopram, oxaprozin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>oxcarbazepine<p>oxcarbazepine will increase the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>oxycodone<p>oxycodone increases effects of escitalopram by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Opioids may enhance the serotonergic effects of SSRIs and increase risk for serotonergic syndrome.</p></li><li>parecoxib<p>escitalopram, parecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>pasireotide<p>escitalopram and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>pentazocine<p>escitalopram and pentazocine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>pentobarbital<p>pentobarbital will decrease the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>phenobarbital<p>phenobarbital will decrease the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>piroxicam<p>escitalopram, piroxicam.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>primidone<p>primidone will decrease the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>quetiapine<p>quetiapine, escitalopram.
Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.</p></li><li>quinine<p>escitalopram and quinine both increase  QTc interval. Use Caution/Monitor.</p></li><li>rifampin<p>rifampin will decrease the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>rilpivirine<p>rilpivirine increases toxicity of escitalopram by QTc interval. Use Caution/Monitor. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsades de Pointes.</p></li><li>ritonavir<p>ritonavir increases levels of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Increased risk of serotonin syndrome.</p></li><li>rizatriptan<p>rizatriptan and escitalopram both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>safinamide<p>escitalopram, safinamide.
Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Monitor patients for symptoms of serotonin syndrome if SSRIs are coadministered with safinamide.</p></li><li>salicylates (non-asa)<p>escitalopram, salicylates (non-asa).
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>salsalate<p>escitalopram, salsalate.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>same<p>escitalopram and same both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>secobarbital<p>secobarbital will decrease the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>sodium sulfate/potassium sulfate/magnesium sulfate<p>escitalopram, sodium sulfate/potassium sulfate/magnesium sulfate. Other (see comment). Use Caution/Monitor. 
Comment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.</p></li><li>sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol<p>escitalopram, sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol. Other (see comment). Use Caution/Monitor. 
Comment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.</p></li><li>sorafenib<p>sorafenib and escitalopram both increase  QTc interval. Use Caution/Monitor.</p></li><li>sulfasalazine<p>escitalopram, sulfasalazine.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>sulindac<p>escitalopram, sulindac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>sumatriptan<p>sumatriptan and escitalopram both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>sumatriptan intranasal<p>sumatriptan intranasal and escitalopram both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>sumatriptan transdermal<p>sumatriptan transdermal and escitalopram both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>tapentadol<p>escitalopram and tapentadol both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>telaprevir<p>telaprevir, escitalopram. Other (see comment). Use Caution/Monitor. 
Comment: Concentrations of escitalopram were decreased when co-administered with telaprevir. Selective serotonin reuptake inhibitors such as escitalopram have a wide therapeutic index, but doses may need to be adjusted when combined with telaprevir.</p></li><li>tolfenamic acid<p>escitalopram, tolfenamic acid.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>tolmetin<p>escitalopram, tolmetin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>tramadol<p>escitalopram and tramadol both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>valerian<p>valerian and escitalopram both increase  sedation. Use Caution/Monitor.</p></li><li>vorapaxar<p>escitalopram, vorapaxar.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive antiplatelet effect may occur; SSRIs and SNRIs may cause platelet serotonin depletion .</p></li><li>voriconazole<p>voriconazole will increase the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>zolmitriptan<p>zolmitriptan and escitalopram both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li>